International consensus guidance for management of myasthenia gravis: 2020 update
Objective To update the 2016 formal consensus-based guidance for the management of
myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October …
myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October …
Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals
D Menon, V Bril - Drugs, 2022 - Springer
Myasthenia gravis (MG) is a chronic, fluctuating, antibody-mediated autoimmune disorder
directed against the post-synaptic neuromuscular junctions of skeletal muscles, resulting in …
directed against the post-synaptic neuromuscular junctions of skeletal muscles, resulting in …
Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 …
Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating
autoimmune disease. New treatments for this disease are needed because conventional …
autoimmune disease. New treatments for this disease are needed because conventional …
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
JF Howard, S Bresch, A Genge… - The Lancet …, 2023 - thelancet.com
Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating rare
disease, often accompanied by high treatment burden and with an unmet need for more …
disease, often accompanied by high treatment burden and with an unmet need for more …
Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
A Padmanabhan, L Connelly‐Smith… - Journal of clinical …, 2019 - Wiley Online Library
ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double …
JF Howard, K Utsugisawa, M Benatar, H Murai… - The Lancet …, 2017 - thelancet.com
Background Complement is likely to have a role in refractory generalised myasthenia gravis,
but no approved therapies specifically target this system. Results from a phase 2 study …
but no approved therapies specifically target this system. Results from a phase 2 study …
Randomized trial of thymectomy in myasthenia gravis
Background Thymectomy has been a mainstay in the treatment of myasthenia gravis, but
there is no conclusive evidence of its benefit. We conducted a multicenter, randomized trial …
there is no conclusive evidence of its benefit. We conducted a multicenter, randomized trial …
Fatigue as a symptom or comorbidity of neurological diseases
Fatigue, best described as an overwhelming feeling of tiredness and exhaustion, occurs in
the context of various neurological diseases. The high prevalence of fatigue as either a …
the context of various neurological diseases. The high prevalence of fatigue as either a …
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders
JJGM Verschuuren, J Palace, H Murai… - The Lancet …, 2022 - thelancet.com
Summary Myasthenia gravis and Lambert-Eaton myasthenic syndrome are antibody-
mediated autoimmune diseases of the neuromuscular junction that usually present with …
mediated autoimmune diseases of the neuromuscular junction that usually present with …